Two low-cost spiro[fluorene-9,9 0 -xanthene] (SFX)-based 3D organic hole transport materials (HTMs), termed X54 and X55, were tailor-made by a one-pot synthesis approach for perovskite solar cells (PSCs). PSC devices based on X55 as the HTM show a very impressive power-conversion efficiency of 20.8% under 100 mW$cm À2 AM1.5G solar illumination, which is much higher than the PCE of the reference devices based on X54 (13.6%) and the standard HTM-Spiro-OMeTAD (18.8%) under the same conditions. HIGHLIGHTS Two SFX-based 3D oligomers were tailor-made by a one-pot synthesis approachOne of the oligomers, X55, was successfully applied in highly efficient PSCs High efficiency of 20.8% was achieved with X55 as the hole transport material The low-cost 3D HTMs can render a PCE close to 21% in PSCs Xu et al., Chem 2, 676-687 May 11, 2017 ª 2017 Elsevier Inc. http://dx. SUMMARYThe power-conversion efficiencies (PCEs) of perovskite solar cells (PSCs) have increased rapidly from about 4% to 22% during the past few years. One of the major challenges for further improvement of the efficiency of PSCs is the lack of sufficiently good hole transport materials (HTMs) to efficiently scavenge the photogenerated holes and aid the transport of the holes to the counter-electrode in the PSCs. In this study, we tailor-made two low-cost spiro[fluorene-9,9 0xanthene] (SFX)-based 3D oligomers, termed X54 and X55, by using a one-pot synthesis approach for PSCs. One of the HTMs, X55, gives a much deeper HOMO level and a higher hole mobility and conductivity than the state-of-theart HTM, Spiro-OMeTAD. PSC devices based on X55 as the HTM show a very impressive PCE of 20.8% under 100 mW$cm À2 AM1.5G solar illumination, which is much higher than the PCE of the reference devices based on Spiro-OMeTAD (18.8%) and X54 (13.6%) under the same conditions.

Although photodynamic therapy (PDT) has thrived as a promising treatment, highly active photosensitizers (PSs) and intense light power can cause treatment overdose. However, extra therapeutic response probes make the monitoring process complicated, ex situ and delayed. Now, this challenge is addressed by a self-reporting cationic PS, named TPE-4EP+, with aggregation-induced emission characteristic. The molecule undergoes mitochondria-to-nucleus translocation during apoptosis induced by PDT, thus enabling the in situ real-time monitoring via fluorescence migration. Moreover, by molecular charge engineering, we prove that the in situ translocation of TPE-4EP+ is mainly attributed to the enhanced interaction with DNA imposed by its multivalent positive charge. The ability of PS to provide PDT with real-time diagnosis help control the treatment dose that can avoid excessive phototoxicity and minimize potential side effect. Future development of new generation of PS is envisioned.